Comparison of ceftriaxone and ampicillin plus chloramphenicol for the therapy of acute bacterial meningitis
Open Access
- 1 September 1985
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 28 (3) , 361-368
- https://doi.org/10.1128/aac.28.3.361
Abstract
Ceftriaxone, a new third-generation cephalosporin, appears to be promising for the therapy of acute bacterial meningitis. The 90% MBCs of ceftriaxone against 54 recent cerebrospinal fluid isolates of Streptococcus pneumoniae, Neisseria meningitidis, and Haemophilus influenzae were less than or equal to 0.06 to 0.25 micrograms/ml. We examined the efficacy and safety of ceftriaxone therapy of meningitis in Bahia, Brazil. The study was conducted in two phases; in phase A, ceftriaxone was coadministered with ampicillin. The mean cerebrospinal fluid concentrations of ceftriaxone 24 h after an intravenous dose of 80 mg/kg were 4.2 and 2.3 micrograms/ml on days 4 to 6 and 10 to 12 of therapy, respectively. These concentrations were 8- to more than 100-fold greater than the 90% MBCs against the relevant pathogens. In phase B, ceftriaxone (administered once daily at a dose of 80 mg/kg after an initial dose of 100 mg/kg) was compared with conventional dosages of ampicillin and chloramphenicol in a prospective randomized trial of 36 children and adults with meningitis. The groups were comparable based on clinical, laboratory, and etiological parameters. Ceftriaxone given once daily produced results equivalent to those obtained with ampicillin plus chloramphenicol, as judged by cure rate, case fatality ratio, resolution with sequelae, type and severity of sequelae, time to sterility of cerebrospinal fluid, and potentially drug-related adverse effects. The cerebrospinal fluid bactericidal titers obtained 16 to 24 h after ceftriaxone dosing were usually 1:512 to greater than 1:2,048 even late in the treatment course, compared with values of 1:8 to 1:32 in patients receiving ampicillin plus chloramphenicol. Ceftriaxone clearly deserves further evaluation for the therapy of meningitis; the optimal dose, dosing frequency (every 12 h or every 24 h), and duration of therapy remain to be determined.This publication has 40 references indexed in Scilit:
- The potential uses of ceftriaxoneEuropean Journal of Clinical Microbiology & Infectious Diseases, 1983
- Once-daily administration of ceftriaxone in the treatment of meningitis and other serious infections in childrenEuropean Journal of Clinical Microbiology & Infectious Diseases, 1983
- Comparison of ceftriaxone with standard therapy for bacterial meningitisThe Journal of Pediatrics, 1983
- Statewide survey of the antimicrobial susceptibilities of Haemophilus influenzae producing invasive disease in TennesseeThe Pediatric Infectious Disease Journal, 1983
- Bactericidal versus Bacteriostatic Antibiotic Therapy of Experimental Pneumococcal Meningitis in RabbitsJournal of Clinical Investigation, 1983
- Ceftriaxone therapy of group B streptococcal bacteraemia and meningitis in infant ratsJournal of Antimicrobial Chemotherapy, 1983
- Single-dose ceftriaxone pharmacokinetics in pediatric patients with central nervous system infectionsThe Journal of Pediatrics, 1983
- In-vitro and in- vivo efficacy of ceftriaxone, moxalactam, and chloramphenicol against Haemophilus influenzae type bJournal of Antimicrobial Chemotherapy, 1982
- The Pharmacologic Basis for Moxalactam Therapy for Gram-Negative Enteric Bacillary Meningitis of InfancyClinical Infectious Diseases, 1982
- Meningitis due to Haemophilus influenzae type b resistant to ampicillin and chloramphenicolThe Journal of Pediatrics, 1980